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Abstract 
It has recently been shown that ROR1, a member of the receptor tyrosine 
kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic 
Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this 
comparative study the expression profile of ROR1 mRNA was investigated in 
Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the 
results were compared with those previously reported in our Iranian ALL 
patients. RT-PCR was performed on bone marrow and/or peripheral blood 
samples of 84 CLL and 12 AML patients. CLL samples were classified into im-
munoglobulin heavy chain variable region (IGHV) gene mutated (n=55) and 
unmutated (n=29) and also indolent (n=42) and progressive (n=39) subtypes.  
ROR1 expression was identified in 94% of our CLL patients, but none of the 
AML patients expressed ROR1. No significant differences were observed be-
tween different CLL subtypes for ROR1 expression. Taken together the present 
data and our previous results on ROR1 expression in ALL, our findings propose 
ROR1 as a tumor-associated antigen overexpressed in a large proportion of 
lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of 
ROR1 seems to be associated to lineage and differentiation stages of leukemic 
cells with a potential implication for immunotherapy.   
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Introduction 
ROR1 is a member of the family of tyrosine 
kinase receptors which is highly conserved 
among various species (1). Gene knockout 
studies in mice have shown the critical devel-
opmental role of ROR1 in heart and skeletal  
 
 
 
 
 
organogenesis (2). Functional ROR1 ligands 
have remained unknown, though secreted pro-
teins of the wingless-type MMTV integration 
site (Wnt) family have recently been proposed 
as ligand candidates (3,4) and Wnt5a was 
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shown to bind Ror1 (5). Ten years after identi-
fication of ROR1 (1), gene expression profiling 
of B cell malignancies on a genomic scale 
displayed ROR1 overexpression in leukemic 
B cells of Chronic Lymphocytic Leukemia 
(CLL) (6,7).  
CLL represents a heterogeneous disease 
with a highly variable prognosis characterized 
by the gradual accumulation of small mature 
CD19+/CD5+/ CD23+ B cells (8). It has a very 
variable clinical course, with survival ranging 
from months to decades (9). The mutational 
status of the immunoglobulin heavy chain 
variable region (IGHV) genes categorizes the 
disease into indolent non-progressive and pro-
gressive entities which has been confirmed as 
an important prognostic marker in prospective 
clinical trials (10). Leukemic CLL cells from 
patients with indolent clinical course typically 
express mutated IGHV, whereas patients with 
aggressive clinical course typically express 
unmutated IGHV (11,12).  
Recently, two studies have separately dem-
onstrated that Ror1 protein is uniformly ex-
pressed in all CLL samples independent of 
molecular and clinical heterogeneity or muta-
tional status, whereas normal B cells, other 
normal blood cells, and normal adult tissues 
do not express cell surface Ror1 (11,13). Fur-
thermore, the expression of ROR1 gene has 
recently been reported in both tumor tissues 
and Peripheral Blood Mononuclear Cells 
(PBMCs) of renal cancer patients (14) and non-
Hodgkin lymphomas (15,16).  
Our recent investigation in a group of Iran-
ian patients with Acute Lymphoblastic Leuke-
mia (ALL) demonstrated ROR1 overexpres-
sion in about 40% of patients (17).  Little is 
known about the expression pattern of ROR1 
in myeloid leukemias and in Iranian patients 
with CLL. In the present study we investi-
gated ROR1 expression in Iranian patients 
with CLL and Acute Myelogenous Leukemia 
(AML) and compared the results with our pre-
vious findings in Iranian patients with ALL.  
 
 
 
Materials and Methods 
 
Patients and controls 
Heparinized Bone Marrow (BM) and/or 
Peripheral Blood (PB) samples were obtained 
from 84 CLL (only PB) and 12 AML (7 pair-
ed BM and PB, 4 BM, and one PB) Iranian 
patients attending the Hematology and Oncol-
ogy Clinics of the Vali-Asr hospital affiliated 
to Tehran University of Medical Sciences and 
the Oncology Clinics of Firozgar and Ali-As-
ghar hospitals, affiliated to Iran University of 
Medical Sciences. A consent letter was taken 
from all patients or their parents and the study 
was approved by the Ethical Committee of 
Tehran University of Medical Sciences. Hep-
arinized PB samples collected from 33 normal 
healthy donors (13 children with a mean age 
of 7.1 years and 20 adults with a mean age of 
42.7 years) served as controls to determine 
baseline ROR1 expression and cut-off value. 
Nucleotide sequence analysis of the IGHV 
genes of the leukemic cells has allowed clas-
sification of the CLL patients into mutated 
(n=55) and unmutated (n=29) groups, based 
on the presence of more than 2% somatic 
mutation compared to the germline sequence 
(18). The patients were clinically classified into 
indolent (n=42) and progressive (n=39) sub-
types (19). Diagnosis of AML was based on 
cytomorphological findings (FAB criteria) 
and immunophenotypic characteristics of BM 
leukemic cells (20). Major demographic fea-
tures of CLL and AML patients have been 
published (19, 20). 
 
ROR1 PCR 
PBMCs of all subjects were isolated by 
density-gradient centrifugation using Histo-
paque (Sigma, St. Louis, MO). RNA extrac-
tion and cDNA synthesis were performed as 
previously described (21). PCR amplification 
was performed using ROR1-specific primers: 
5'-CTG CTG CCC AAG AAA CAG AG-3' as 
sense and 5'-CAT AGT GAA GGA AGC 
TGT GAT CT-3' as antisense (Gen Bank ac-
cession No. NM 005012) and ȕ-actin-specific 
primers: 5'-ATG GCC ACG GCT GCT TCC  
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AGC-3' as sense and 5'-CAG GAG GAG 
CAA TGA TCT TGA T-3' as antisense (Gen 
Bank accession No. NM_001101.2).  
Briefly, 25 µl of PCR mixture were 
prepared using 2.5 µl of 10× PCR buffer, 1 µl 
(for ROR1) and 3 µl (for ȕ-actin) of 25 mM 
MgCl2, 1.5 µl dNTPs (10 mM), 0.5 µl of each 
primer (10 pmol/µl), 0.1 µl of Taq-DNA poly-
merase (5 U/µl; CinnaGen, Iran) and 3 µl (for 
ROR1) and 1 µl (for ȕ-actin) of cDNA. PCR 
was followed by 37 cycles for ROR1 and 26 
cycles for ȕ-actin. Each cycle of ROR1 amp-
lification consisted of 92 °C for 30 s, 62 °C 
for 30 s, 72 °C for 1 min and finally 72 °C for 
10 min. Each cycle of ȕ-actin amplification 
consisted of 92 °C for 30 s, 60 °C for 30 s, 
72°C for 30 s and finally 72 °C for 10 min. 
The amplicon sizes of ROR1 and ȕ-actin PCR 
products were 545 and 321 bp, respectively. 
PCR products were finally visualized by run-
ning agarose gel (1.5%) electrophoresis con-
taining ethidium bromide.  
Both ROR1 and ȕ-actin products of each 
sample were run simultaneously in a single 
lane to minimize between-run variations and 
enhance precision of the assay. After electro-
phoresis, images were taken using a gel docu-
mentation system (UVP, LMS-20E, USA). 
ROR1 and ȕ-actin band densities were de-
termined by Labworks 4.0 software (UVP, 
USA), and the ratio of the two bands was 
calculated for each sample and multiplied by 
100. 
 
Immunophenotyping of leukemic cells 
Mononuclear cells from BM or PB of CLL 
and AML patients were immunophenotyped 
by flow cytometry using FITC- or PE-conju-
gated monoclonal antibodies (mAbs), as pre-
viously described (19,20). Staining of at least 
20% of the leukemic cells after subtraction of 
background staining with isotype matched 
conjugated mAbs of irrelevant specificity was 
considered positive. 
 
Statistical analysis 
Analyses were conducted using the SPSS 
statistical package (SPSS, Chicago, IL). Stat-
istical analyses of the results were performed 
using Chi-Square, Fisher’s exact tests, and 
Mann-Whitney U tests as appropriate. P-
values of less than 0.05 were considered sig-
nificant. 
 
Results 
Relative expression of ROR1 mRNA levels 
in patients and normal subjects was deter-
mined by calculation of the ratio of ROR1 
PCR product band density to that of ȕ-actin. 
The level of expression of ROR1 mRNA was 
determined in all samples by visualization of 
the corresponding PCR product following 
electrophoresis. Representative RT-PCR re-
sults obtained for a number of patients and 
normal samples are illustrated in figure 1.  
Baseline level of ROR1 expression was as-
signed as mean + 1SD of ROR1/ȕ-actin ratio 
of 33 normal subjects (17). Accordingly, 4 of 
33 normal samples were found to be positive. 
Of the 84 CLL samples 79 (94%) were posi-
tive (Figure 2). However, no significant 
differences were observed between indolent 
(n=42) and progressive (n=39) subtypes. 
Similarly, no substantial differences were ob-
served between IGHV mutated (n=55) and 
unmutated (n=29) groups of patients (Figure 
3).  
Comparison of the expression levels of 
ROR1 between CLL and normal subjects 
demonstrated significantly higher expression 
levels in CLL patients (p < 0.0001) (Figure 2). 
Contrary to CLL, none of the AML patients 
was found to express ROR1 mRNA (Figures 
1 and 2). There is no significant difference of 
Figure 1. Representative expression profile of ROR1 
mRNA in peripheral blood (PB) or bone marrow (BM) 
samples of a number of patients and healthy subjects. PCR 
amplicons of ROR1 (545 bp) and ȕ-actin (321 bp) genes 
were electrophoresed on 1.5% ethidium bromide- stained 
gel and photographed. Lane 1: size marker; Lanes 2-5: 
CLL (PB); Lanes 6-9: AML (6 and 8: PB and 7 and 9: 
BM); Lanes 10-12: healthy subjects (PB) 
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ROR1 expression between BM and PB sam-
ples of our AML patients (data not presented).  
 
Discussion 
Lymphoid and myeloid malignancies are a 
diverse group of neoplasms derived from 
clonal expansion of lymphocytes and mono-
cytes arrested at different stages of differenti-
ation (22). Exploration of the immunopheno-
types of leukemic cells in relation to the nor-
mal hemopoietic differentiation reveals pro-
files that closely mimic those of correspond-
ing normal cells at equivalent levels of matur-
ation (23). However, the gene expression pro-
file of the leukemic cells is not the same as 
that of the normal counterpart and displays 
many similarities and differences (7,24-27). Gene 
expression profile of the leukemic B cells in 
follicular lymphoma, hairy cell leukemia and 
CLL has been shown to resemble the 
germinal center or the memory stage of 
differentiation (7,24,28,29). Nevertheless, some 
genes such as fibromodulin (FMOD), ROR1 
and some members of the WNT gene family 
are selectively overexpressed in the leukemic 
CLL B cells and are not detected in normal B 
cells (7,13,24,30,31). 
ROR1 has recently been extensively inves-
tigated due to its potential biological func-
tions as a member of receptor tyrosine kinase 
family. Although its counterparts in other 
species fulfill diverse recognized biological 
functions, its role in human still remains un-
known (32). In addition, functional ROR1 li-
gands have remained unknown, even though 
Fukuda et al showed ROR1 could bind Wnt5a 
(5). They found that Wnt5a induced activation 
of NF-țB when coexpressed with ROR1 in 
HEK293 cells and enhanced the survival of 
CLL cells in vitro, an effect that could be neu-
tralized by post-treatment with anti-ROR1 
antisera (5). It has  recently been demonstrated 
that IL-6 activated Stat3 binds to the ROR1 
promoter and activates ROR1 in CLL cells 
(33). Interestingly, systematic knock down of 
all known and putative human kinases in the 
human cervical cancer cell line HeLa by 
siRNA, has introduced ROR1 as an inhibitor 
of apoptosis (34), suggesting its role in etio-
pathogenesis of the implicated tumors.  
This assumption is supported by our results 
of ROR1 expression in 94% and 40% of 
Iranian CLL and ALL patients, respectively 
(Figure 2 and (17)). The expression level of 
ROR1 in our CLL patients was significantly 
higher than that obtained in our earlier study 
for the Iranian ALL patients (17) (p<0.0001). 
Compatible with our results Basker et al and 
Daneshmanesh et al have recently shown 
ROR1 expression both at mRNA and protein 
levels in all Caucasian CLL patients investi-
gated (11,13). At protein level, Ror1 expression 
Figure 3. Representative expression profile of ROR1 in 
different subgroups of CLL patients. PCR amplicons of 
ROR1 (545 bp) and ȕ-actin (321 bp) genes were electro-
phoresed on 1.5% ethidium bromide-stained agarose gel 
and photographed. Lanes 1-4: patients with indolent 
disease; Lanes 5-7: patients with progressive disease; lane 
8: size marker; Lanes 9-11: patients with mutated leukemic 
cells; Lanes 12-14: patients with unmutated leukemic cells  
 
Figure 2. Relative expression levels of ROR1 mRNA in 
CLL, ALL and AML patients and normal subjects. The 
horizontal line denotes the cutoff value obtained from the 
normal samples; the data of ALL patients has been taken 
from ref 17. Relative expression of ROR1 mRNA levels in 
samples was determined by calculation of the ratio of 
ROR1 PCR product band density to that of ȕ-actin. 
Baseline level of ROR1 expression was assigned as mean + 
1SD of ROR1/ ȕ-actin ratio of normal subjects. 
*** :  p-values of less than 0.0001 
** : p-values of less than 0.005 
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is selectively expressed on the surface of B-
CLL cells, whereas normal B cells, other nor-
mal blood cells and normal adult tissues do 
not express cell surface Ror1 (5,11,13). In add-
ition to CLL ROR1 is also expressed in non-
Hodgkin's lymphomas, with high expression 
in mantle cell lymphoma and moderate ex-
pression in marginal zone lymphoma (15,16), but 
not in major adult tissues apart from low 
levels in adipose tissue and at an early stage 
of B-cell development (15). 
Interestingly, ROR1 mRNA was complete-
ly negative in all our AML patients (12/12) 
(Figure 2). There is only one detailed report 
on ROR1 expression in AML, which is in line 
with our results. Muller-Tidow et al have ana-
lyzed expression of all human receptor tyro-
sine kinases (n=56) in malignant tumors of 
different origins and normal control samples 
by quantitative real-time RT-PCR. They show-
ed that the AML samples expressed only 20 
different receptor tyrosine kinases, but sur-
prisingly none of their 85 AML patients ex-
pressed ROR1, with the exception of only one 
sample with weak expression (35). No publish-
ed data is available regarding ROR1 expres-
sion at protein level in AML. It is important 
to study more cases of AML as well as other 
myeloid leukemias, such as chronic myeloid 
leukemia and promyelocytic leukemia from 
different ethnic origins to prove its lack of 
association to the myeloid lineage. 
 
Conclusion 
In conclusion the present study provides 
evidence suggesting that expression of ROR1 
might be associated to lineage and differenti-
ation stages of leukemic cells with a potential 
implication for immunotherapy.  
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